C4 Therapeutics Management Team
10 Team Members
C4 Therapeutics has 10 executives. C4 Therapeutics's founder is Marc A. Cohen. C4 Therapeutics's current Chief Executive Officer, President is Andrew J Hirsch.
You May Also Like
Amphista Therapeutics is a biopharmaceutical company that creates cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease-causing proteins.
Pin Therapeutics is a pharmaceutical company that creates therapeutic products based on chemical biology-driven protein degradation, including PROTAC technology. The company aims to develop PROTAC compounds for oncology, neurodegenerative diseases, and cardiovascular indications based on disease-agnostic approaches.
FIMECS is a drug discovery biotech firm focused on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases.
Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients.
Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options for patients.
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. The drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.